Can, M. Et Al. 2012. Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.15, no.6 , 526-530.

Can, M., Aydin, S. Z., Nigdelioglu, A., Atagunduz, P., & Direskeneli, H., (2012). Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.15, no.6, 526-530.

Can, Meryem Et Al. "Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience," INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.15, no.6, 526-530, 2012

Can, Meryem Et Al. "Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience." INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.15, no.6, pp.526-530, 2012

Can, M. Et Al. (2012) . "Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience." INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , vol.15, no.6, pp.526-530.

@article{article, author={Meryem Can Et Al. }, title={Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience}, journal={INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES}, year=2012, pages={526-530} }